JP2007513190A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513190A5
JP2007513190A5 JP2006542888A JP2006542888A JP2007513190A5 JP 2007513190 A5 JP2007513190 A5 JP 2007513190A5 JP 2006542888 A JP2006542888 A JP 2006542888A JP 2006542888 A JP2006542888 A JP 2006542888A JP 2007513190 A5 JP2007513190 A5 JP 2007513190A5
Authority
JP
Japan
Prior art keywords
times per
present
per week
factor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006542888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513190A (ja
JP4738346B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/041070 external-priority patent/WO2005055950A2/en
Publication of JP2007513190A publication Critical patent/JP2007513190A/ja
Publication of JP2007513190A5 publication Critical patent/JP2007513190A5/ja
Application granted granted Critical
Publication of JP4738346B2 publication Critical patent/JP4738346B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006542888A 2003-12-03 2004-12-03 ＧｌｙｃｏＰＥＧ化された第ＩＸ因子 Expired - Fee Related JP4738346B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US52708903P 2003-12-03 2003-12-03
US60/527,089 2003-12-03
US53938704P 2004-01-26 2004-01-26
US60/539,387 2004-01-26
US59274404P 2004-07-29 2004-07-29
US60/592,744 2004-07-29
US61451804P 2004-09-29 2004-09-29
US60/614,518 2004-09-29
US62338704P 2004-10-29 2004-10-29
US60/623,387 2004-10-29
PCT/US2004/041070 WO2005055950A2 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix

Publications (3)

Publication Number Publication Date
JP2007513190A JP2007513190A (ja) 2007-05-24
JP2007513190A5 true JP2007513190A5 (https=) 2008-08-28
JP4738346B2 JP4738346B2 (ja) 2011-08-03

Family

ID=34682416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542888A Expired - Fee Related JP4738346B2 (ja) 2003-12-03 2004-12-03 ＧｌｙｃｏＰＥＧ化された第ＩＸ因子

Country Status (10)

Country Link
EP (1) EP1694315A4 (https=)
JP (1) JP4738346B2 (https=)
KR (1) KR101209111B1 (https=)
AU (1) AU2004296860B2 (https=)
BR (1) BRPI0417341A (https=)
CA (1) CA2549413A1 (https=)
IL (1) IL175661A0 (https=)
MX (1) MXPA06006023A (https=)
NZ (1) NZ546733A (https=)
WO (1) WO2005055950A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7338933B2 (en) 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
KR101146160B1 (ko) 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1937719A4 (en) * 2005-08-19 2010-11-24 Novo Nordisk As GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
ES2516694T3 (es) * 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US20100041872A1 (en) * 2006-10-04 2010-02-18 Defrees Shawn Glycerol linked pegylated sugars and glycopeptides
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
AU2008245524A1 (en) * 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
AU2008311973B2 (en) * 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
NZ598193A (en) * 2007-12-27 2012-12-21 Baxter Int Chemically Modified Factor IX
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
CA2721683A1 (en) * 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
CN102497884A (zh) 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2461821A4 (en) * 2009-07-31 2013-07-03 Bayer Healthcare Llc MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF
WO2011064247A1 (en) 2009-11-24 2011-06-03 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
CN113573726A (zh) 2019-03-19 2021-10-29 康诺贝林伦瑙有限公司 因子ix变体及其在治疗中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
MXPA00005376A (es) * 1997-12-01 2002-07-02 Neose Technologies Inc Sintesis enzimatica de gangliosidos.
EP2042196B1 (en) * 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)

Similar Documents

Publication Publication Date Title
JP2007513190A5 (https=)
Liu et al. Polymersome wound dressing spray capable of bacterial inhibition and H2S generation for complete diabetic wound healing
US8003696B2 (en) Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
JP2019515908A5 (https=)
IL161628A0 (en) Pharmaceutical dosage form with multiple coatings
CA3162623A1 (en) Aerosolization systems, methods, and apparatuses
CN108348894A (zh) 用于化合物活化以及臭氧降解的臭氧解
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
Yang et al. Nonlinear and mixed inhibitory effect of matrine on the cytotoxicity of oligomeric amyloid-β protein
US11571455B2 (en) Methods and compositions for treating alcoholic liver disease
EP4255391A1 (en) Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
HRP960070A2 (en) Use of quinoxaline and protease inhibitors in a composition for the treatment of aids and/or hiv infections
CN113365617B (zh) 用于医学疾病治疗的一氧化碳前药
CN101346137A (zh) 含有孔布勒塔斯塔坦与抗癌剂的组合物
JP2018123140A (ja) 活性成分（ｉ）含有組成物及びその製造方法
EP1996014B1 (en) Composition for treating bacterial, viral, fungal diseases, inflammation and pain
JP2008517977A5 (https=)
Raij Mechanisms of vascular injury: the emerging role of the endothelium.
JP2016521760A (ja) がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ
WO2007132280A1 (en) Isatin and its derivatives for use as a medicament
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
NO20013901L (no) Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter
CN1747726A (zh) 一种用于治疗hiv－1和hiv－2的治疗性组合物